NIH launched Home Test to Treat, a pilot COVID-19 telehealth program
On Jan. 5, 2023, the National Institutes of Health, in collaboration with the Administration for Strategic Preparedness and…
-
-
Spanish, Italian and French Health Authorities expanded recommendations for use of Novavax COVID-19 vaccine
On Jan. 5, 2023, Novavax announced that Spain’s Public Health Commission, Italy’s Ministry of Health, and France’s Haute…
-
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
-
U.S. Department of Health and Human Services increased access to Tamiflu through the Strategic National Stockpile
On Dec. 21, 2022, the U.S. Department of Health and Human Services (HHS), through the Administration for Strategic…
-
FDA approved Roche’s Actemra for treatment of COVID-19 in hospitalised adults
On Dec. 21, 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Actemraﾮ (tocilizumab)…
-
Study revealed that duration of exposure to COVID-19 plays major role in risk of catching the virus
On Dec. 20, 2022, the University of Oxford announced study results using data from 7 million people notified…
-
German Health Authority expanded recommendation for use of Novavax COVID-19 vaccine as a booster
On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its…
-
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
Swiss and French health authorities expanded recommendations for use of Nuvaxovid COVID-19 vaccine as booster
On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite…
-
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
-
COVID-19 vaccine from Washington University in St. Louis approved for use as booster in India
On Dec. 9, 2022, Washington University in St. Louis announced that it’s nasal COVID-19 vaccine technology had been…
-
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
-
Biotechnology | COVID-19 | FDA | Vaccine
Pfizer and BioNTech received U.S. FDA EUA for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children
On Dec. 8, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted Emergency Use…
-
Biotechnology | COVID-19 | Therapeutics | Vaccine | WHO
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | NIH | Non-Profit Research | Therapeutics | Vaccine
Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
-
Biotechnology | COVID-19 | Medicine | Vaccine
Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster demonstrating improved immune response against Omicron sublineages
On Nov. 18, 2022, Pfizer and BioNTech announced results from an analysis examining the immune response induced by…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
-
U.S. pandemic death toll higher than in 20 peer countries
On Nov. 18, 2022, the Journal of the American Medical Association reported that the U.S. experienced high COVID-19…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
-
Pfizer and BioNTech announced updated data for Omicron BA.4/BA.5-adapted bivalent booster
On Nov. 4, 2022, Pfizer and BioNTech announced updated data from a Phase 2/3 clinical trial demonstrating a…
-
University of Missouri study found Mpox mutations caused virus to spread rapidly, evade drugs and vaccines
On Nov. 3, 2022, researchers have identified the specific mutations in the mpox virus that contribute to its…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
Biotechnology | COVID-19 | Diagnostics | Disease | NIH | Therapeutics
NIH-funded study showed blood pressure levels rose during pandemic
On Nov. 1, 2022, the National Institutes of Health (NIH) announced that adults with hypertension saw a small,…
-
Japan approved partial change to a NDA for Omicron-targeting bivalent booster COVID-19 vaccine
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
-
INOVIO Discontinued internal efforts to develop INO-4800 as COVID-19 heterologous booster vaccine Candidate
On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800…
